Welcome to the September 2024 edition of the Rare Mutations and Fusions newsletter from LUNGevity's Patient Gateways.
September is an exciting time for cancer news, with researchers presenting data at major conferences, including the World Conference on Lung Cancer (WCLC). This year, WCLC had important updates in the Rare Mutations and Fusions space.
Two key presentations highlighted progress in treating HER2-positive cancers. These studies complement the FDA approval earlier this year for treating HER2-positive tumors with trastuzumab DXd—which carries the risk of a severe side effect, called interstitial lung disease.
The studies presented at WCLC highlight two drugs, BAY 2927088 and zongertinib, which demonstrated promising results for patients with HER2-positive non-small cell lung cancer (NSCLC).
Both BAY 2927088 and zongertinib showed impressive objective response rates (ORR) of 72% and 67%, respectively. They both showed tolerable safety profiles. In addition, zongertinib showed strong activity for patients with brain metastases, which are common in the HER2-positive NSCLC population. Both drugs show promising results and may soon offer additional options for patients with HER2-positive NSCLC.
Research News
Nature
A real world analysis of secondary BRAF variations after targeted therapy resistance in driver gene positive NSCLC
Published Sep 1, 2024
DocWire News
SOHO-01 and FURTHER: Dr. Xiuning Le Discusses IASLC Presidential Symposium Presentations
Published Sep 11, 2024
Pharmabiz.com
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
Published Sep 10, 2024
USA Life Sciences Database
Phase II Study of Taletrectinib Shows Clinically Meaningful Overall Response and Favorable Safety in Patients with ROS1+ Non-Small Cell Lung Cancer
Published Sep 10, 2024
CheckOrphan
Breakthrough Therapy BAY 2927088 Demonstrates Rapid, Substantial and Durable Efficacy in Patients with HER2-Mutant NSCLC
Published Sep 10, 2024
Drug Discovery World
Over 60% response in lung cancer tumours with rare mutation
Published Sep 10, 2024
PharmaPhorum
WCLC: Bayer, Boehringer face off on HER2 cancers
Published Sep 10, 2024
Drugs.com
FDA Approves Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
Published Jun 17, 2024
Healio
FDA grants accelerated approval to Augtyro for NTRK-positive solid tumors
Published Jun 14, 2024
Clinical Trials Arena
FDA approval makes Enhertu an option for multiple tumour indications
Published Apr 11, 2024
Medscape
FDA Expands Enhertu Indication to HER2-Positive Solid Tumors
Published Apr 8, 2024
Get Connected
There’s Still Time!
Don’t miss this opportunity to chat with Dr. Ross Camidge, an accomplished lung cancer expert from the University of Colorado Cancer Center and Janet Freeman-Daily, an experienced patient advocate, during the Rare Mutations Ask the Expert session at LUNGevity’s International Lung Cancer Survivorship Conference on September 20-21. This free virtual conference brings a full slate of lung cancer specialists and cutting-edge information directly to you! Check out the full agenda and register today.
Join Us for the Rare Mutations Virtual Meetup
This is an easy way to build your community. On the first Wednesday of each month, you can connect with others who understand what it’s like to live with lung cancer with rare mutations and fusions. The next Rare Mutation Meetup is happening on Wednesday, October 2, 2024, at 3 pm ET. Register for this virtual meetup to get a confirmation email with details about how to join the virtual meeting. New attendees are always welcome and encouraged to join! Can’t
make it? Don’t worry, there’s a full list of virtual meetups to fit your schedule.
Have You Seen?
HER2+ NSCLC
HER2 is best known for its role in breast cancer, but it can be found in lung cancer as well. This webinar features lung cancer expert Dr. Ibiayi Dagogo-Jack as she explains the key points every patient with HER2+ NSCLC needs to know.
Safely Bring Yoga, Dietary Supplements, and More into Your Lung Cancer Journey
Integrative oncology adds holistic approaches—such as acupuncture, nutrition, exercise, and mindfulness—into a treatment plan. Research shows these interventions can have a tremendous impact on the quality of life of people going through lung cancer treatment. Unfortunately, they are also topics riddled with myths and falsehoods. LUNGevity spoke to an expert to help sort out the facts from the fiction. In this webinar, Gabriel Lopez, MD, medical director of the Integrative Medicine Center at MD Anderson Cancer Center, explained how integrative medicine can be safely used by people managing a lung cancer diagnosis.
Advice and Insights from
Author and Two-Time Cancer Survivor Kathy Giusti
Kathy Giusti joined LUNGevity for a special conversation about her life as a cancer patient, caregiver, and the founder and former CEO of the Multiple Myeloma Research Foundation. Her involvement with the medical system from these different perspectives inspired her to write her recent book, Fatal to Fearless: 12 Steps to Beating Cancer in a Broken Medical System. Watch the full interview here.
… and there is always so much more to explore on the Rare Mutations & Fusions Patient Gateway.
If you were forwarded this email and you’d like to subscribe to this newsletter, you can sign up here.
If you are looking for more LUNGevity Foundation news, check out LUNGevity’s monthly newsletter.
If you need further assistance along your lung cancer journey, please email us at support@lungevity.org. Our team is always here to assist you.
